Novo Nordisk (NVO) reported better than expected sales for its weight loss therapy Wegovy with its Q3 2024 financials on ...

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

Novo Nordisk reported better-than-expected third-quarter sales for its weight-loss drug Wegovy, calming investor concerns ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same ...

Novo Nordisk's third-quarter sales for Wegovy exceeded expectations, relieving investors concerned about demand slowdown.

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...